Guggenheim Maintains Buy on Neurogene, Raises Price Target to $81

Benzinga Newsdesk www.benzinga.com Positive 80.9%

Neg 0% Neu 0% Pos 80.9%

Guggenheim analyst Debjit Chattopadhyay maintains Neurogene (NASDAQ:NGNE) with a Buy and raises the price target from $69 to $81.